Topnav

Tag Archives | Adcock Ingram

Activate immune support

Winter is here and the relationship between stress and decreased immune function is well known. Stress can increase our chances of developing the common cold and upper respiratory infections. The solution is to counteract this negative effect of stress on our immune system and a solution is now available. (more…)

Continue Reading · 0

Rheumalef launch at SARAA

The South African Rheumatism Arthritis Association congress was recently held at the Pivot Conference Centre, Montecasino. Adcock Ingram sponsored a dinner and presentation for the delegates on 21 May. (more…)

Continue Reading · 0

Once-monthly tablet launched for osteoporosis

Adcock Ingram has launched Boniva – a once-monthly tablet for postmenopausal osteoporosis. The active ingredient, ibandronate (150mg monthly), has shown significant increases in bone mineral density. It also offers vertebral fracture protection, lowering rates of vertebral fractures vs weekly bisphosphonates. Dr Stanley Lipschitz, Specialist Physician and Geriatrician, presented at the Johannesburg event, held at the […]

Continue Reading · 0

Adcock Ingram funds facial surgery

In what will undoubtedly be their best Christmas ever, 43 children from across the Western Cape will this month receive new smiles, or take another step closer to realising that dream.  This will happen as they undergo life-changing surgeries for various facial anomalies as part of the Adcock Ingram Smile Week, hosted at the Tygerberg […]

Continue Reading · 0

Adcock’s ‘hot’ Chile deal

Adcock Ingram showed that it is still on track to grow its foothold in the global emerging pharmaceutical markets, after it announced it is in discussions with one of the largest pharmaceutical companies in Latin America, to buy 100% of Adcock’s shares. Chilean company CFR Pharmaceuticals (CFR) submitted to Adcock Ingram a non-binding offer on […]

Continue Reading · 0

Local Pharmaceutical Plant Will Benefit Industry and Consumers

The pharmaceutical industry is cautiously optimistic about government’s plans to erect a multimillion rand pharmaceutical plant in Gauteng aimed at producing active pharmaceutical ingredients (APIs). The new company, dubbed ‘Ketlaphela’ – a Sesotho word meaning ‘I will live or survive’ – will be jointly run by state-owned Pelchem and Swiss pharmaceutical giant, Lonza. Phase 1 […]

Continue Reading · 0

DPPs: More Confusion as MCC Issues another Withdrawal Order

Confusion is again reigning in the saga surrounding the withdrawal of dextropropoxyphene (DPP)-containing medicines in SA after the Medicines Control Council (MCC) sent out another letter to doctors and pharmacists confirming its April decision to deregister and withdraw all DPPs from the South African market. However, it failed to mention that the appeals process involving […]

Continue Reading · 0

The DPP Debacle: A Case of Rather Be too Safe than Sorry?

The manufacturer of dextropropoxyphene (DPP)-containing drugs in SA, Adcock Ingram, said it is optimistic that its appeal against the Medicines Control Council’s (MCC) decision to cancel the registration of the products will succeed. The company has stressed that the MCC’s decision is subject to the outcome of the appeal process and that the three-month grace […]

Continue Reading · 0